Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win Read more
Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nod Read more
Regeneron ends eye disease trial for anti-CD3 antibody following safety review Read more
This event has passed.
2025 BioInfect Conference
February 5, 2025 @ 8:30 am
The agenda at BioInfect will focus on the issues surrounding the increasing threat of AMR and how it can be addressed.
